ABSTRACT
Objective: The purpose of this study was to evaluate the occurrence of the metabolic syndrome and obesity during the first year after the diagnosis of breast cancer in women undergoing interdisciplinary approach. Methods: In this prospective study, 81 women (age ≥45 years) with recent histological diagnosis of breast cancer, no established cardiovascular disease, who attended at a single specialized center with an interdisciplinary approach (medical, nutritionist, and psychological) were included. Results: Women with metabolic syndrome were considered to have three or more diagnostic criteria: waist circumference >88 cm, triglycerides ≥150 mg/dL, high-density lipoprotein <50 mg/dL, blood pressure ≥130/85 mmHg, and glucose ≥100 mg/dL. Obesity was considered when body mass index >30 kg/m2 and abdominal obesity with waist circumference >88 cm. The evaluations were carried out at three time points: first cancer visit (T0m), 6 months (T6m), and 12 months (T12m). For statistical analysis, the McNemar test was used to compare these time points and the chi-square test was used for trends. The mean age of the patients was 58.4±10.7 years, and 83.3% of them were in the postmenopausal stage. There were no differences in the metabolic syndrome, body mass index, and waist circumference assessments at the indicated time points. When comparing the individual quantitative criteria for metabolic syndrome, there was a statistically significant difference in the values of triglycerides and blood glucose. At times T0m, T6m, and T12m, an increase in the mean triglyceride values was observed, 121, 139.4, and 148.46 mg/dL (p=0.003) and a reduction in the mean glucose values, 106.6, 100.46, and 98.96 mg/dL (p=0.004), respectively. Conclusion: Women with breast cancer subjected to interdisciplinary evaluation did not show an increase in the occurrence of metabolic syndrome and obesity during the first year following their cancer diagnosis.
ABSTRACT
Objective: To assess the pattern of sexual performance in women treated for breast cancer. Methods: This is a cross-sectional study on women treated for breast cancer. Inclusion criteria: to have undergone the first-line therapy for cancer and the cancer not being classified as stage IV. Data on cancer were collected by the analysis of medical records. For the evaluation of sexual performance, women were submitted to individual interviews, with the application of the Quociente Sexual Versão Feminina (QSF) questionnaire. Sexual performance was classified as: bad, unfavorable, regular, good, and excellent. The diagnosis of sexual dysfunction was established to women with score ≤ 60. For descriptive analyses, absolute (n) and relative (%) frequencies were performed, and for the comparison between the quantitative variables the Student's t-test was used. Results: 31 women with a mean age of 55.2 years were included, 35% were classified as clinical stage II, 84% underwent conservative surgery, 65% underwent chemotherapy, and 80% used endocrinotherapy. Regarding sexual performance, 62% spontaneously think about sex, 35% are always interested in sex, and 51.7% have some degree of pain during intercourse. After calculating the score, it was concluded that 6.5% had bad sexual performance; 19.4%, unfavorable; 19.4%, regular; 41.9%, good; and 12.8%, excellent. The mean score was 58.7 points (standard deviation = 21.4, median of 64, minimum of 16, and maximum of 90 points), and 45.2% of women were diagnosed with sexual dysfunction. The provided treatments and the length of follow-up did not have a significant correlation with sexual performance. Conclusion: Most women treated for breast cancer had sexual performance classified as "good and excellent," although a significant percentage had a diagnosis of sexual dysfunction.
ABSTRACT
OBJETIVO: Avaliar a ocorrência de síndrome metabólica (SM) em mulheres na pós-menopausa tratadas de câncer de mama. MÉTODOS: Estudo clínico, transversal, com 158 mulheres na pós-menopausa (amenorreia >12 meses e idade ≥45 anos) tratadas de câncer de mama e livres de doença há pelo menos cinco anos. Por meio de entrevista foram coletados dados clínicos e avaliados o índice de massa corpórea (IMC) e a circunferência da cintura (CC). Na análise bioquímica foram solicitadas dosagens de colesterol total (CT), HDL, LDL, triglicerídeos (TG), glicemia, insulina e proteína C-reativa (PCR). Foram consideradas com SM as mulheres que apresentaram três ou mais critérios diagnósticos: CC>88 cm; TG≥150 mg/dL; HDL colesterol <50 mg/dL; pressão arterial≥130/85 mmHg; glicemia de jejum≥100 mg/dL. Para análise estatística foram empregados o teste t de Student e o teste do χ2. RESULTADOS: A média de idade das pacientes foi de 63,1±8,6 anos, com tempo médio de seguimento de 9,1±4,0 anos. A SM foi diagnosticada em 48,1% (76/158) e entre os critérios diagnósticos, o mais prevalente foi obesidade abdominal (CC>88 cm) afetando 54,4% (86/158) das mulheres. As pacientes sem SM tiveram maior tempo de seguimento quando comparadas àquelas com SM (p<0,05). Em relação ao IMC atual, aquelas sem SM eram em média sobrepeso e aquelas com SM eram obesas (p<0,05). Entre estas, na comparação entre o IMC no momento do diagnóstico do câncer e o atual foi observado ganho significativo de peso (27,8±5,4 versus 33,4±5,4 kg/m²) (p<0,05). O valor médio de PCR foi superior nas mulheres com SM (p<0.05). Na comparação das características tumorais e tratamentos oncológicos não houve diferença significativa entre as mulheres com e sem SM. CONCLUSÃO: Mulheres na pós-menopausa tratadas de câncer de mama têm elevado risco de desenvolver síndrome metabólica e obesidade central.
PURPOSE: To assess the occurrence of metabolic syndrome (MetS) in postmenopausal breast cancer survivors. METHODS: A total of 158 breast cancer survivors were included in this cross-sectional study. Eligibility criteria were: women with amenorrhea >12 months and age ≥45 years, treated for breast cancer and no metastasis for at least five years. Clinical history and anthropometric indicator data (body mass index (BMI), and waist circumference, (WC) were collected. Biochemical parameters, including total cholesterol, HDL, LDL, triglycerides (TG), glucose and C-reactive protein (CRP), were measured. MetS was diagnosed as the presence of at least three of the following diagnostic criteria: WC>88 cm, blood pressure≥130/85 mmHg, triglycerides≥150 mg/dl, HDL <50 mg/dL,and glucose≥100 mg/dL. The Student's t-test and χ2 test were used for statistical analysis. RESULTS: The mean age of breast cancer survivors was 63.1±8.6 years, with a mean follow-up of 9.1±4.0 years. MetS was diagnosed in 48.1% (76/158) and the most prevalent diagnostic criterion was abdominal obesity (WC>88 cm), affecting 54.4% (86/158) of the women. The patients without MetS had a longer follow-up compared those with MetS (p<0.05). Regarding the current BMI, PN average, those without MetS were overweight, and those with MetS were obese (p<0.05). Among the latter, comparison of BMI at the time of cancer diagnosis and current BMI (27.8±5.4 versus 33.4±5.4 kg/m²) showed a significant weight gain (p<0.05). Mean CRP values were higher in women with MetS (p<0.05). In the comparison of tumor characteristics and cancer treatments there was no difference between groups (p>0.05). CONCLUSION: Postmenopausal breast cancer survivors had a higher risk of developing metabolic syndrome and central obesity.